ABVC BioPharma Inc ABVC

Morningstar Rating
$0.93 −0.09 (8.58%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ABVC is trading at a LOCK|>%%l@ premium.
Price
$1.03
Fair Value
LOCK|sYJ$fs
Uncertainty
LOCK|$? k^z#t
1-Star Price
LOCK|^P$%%Mr
5-Star Price
LOCK|?p?jQ?
Economic Moat
LOCK|^Z?
Capital Allocation
—

Trading Information

Previous Close Price
$1.02
Day Range
$0.92–1.05
52-Week Range
$0.71–3.07
Bid/Ask
$0.93 / $0.95
Shares Outstanding
26.69M
Market Cap
$24.89M
Volume/Avg
104,609 / 107,665

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
30.62
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
19

Valuation

Metric
ABVC
Price/Earnings (Normalized)
—
Price/Book Value
2.38
Price/Sales
30.62
Price/Cash Flow
—
Price/Earnings
ABVC

Financial Strength

Metric
ABVC
Quick Ratio
0.05
Current Ratio
0.07
Interest Coverage
−48.82
Quick Ratio
ABVC

Profitability

Metric
ABVC
Return on Assets (Normalized)
−20.48%
Return on Equity (Normalized)
−39.01%
Return on Invested Capital (Normalized)
−26.83%
Return on Assets
ABVC

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|<%@d^$LOCK|v#@<W$126B
Moderna Inc
MRNA
LOCK|j!?vk?LOCK|#bP$90B
Regeneron Pharmaceuticals Inc
REGN
LOCK|<gS$$l<LOCK|>@P#&$80B
argenx SE ADR
ARGX
LOCK|!y^TZ?LOCK|GfL$53B
BeOne Medicines Ltd ADR
ONC
LOCK|#@#WwQLOCK|SqY$41B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|Mz@hTNLOCK|&@rsl$30B
Royalty Pharma PLC Class A
RPRX
LOCK|!vTB&&JLOCK|FL&^$26B
Incyte Corp
INCY
LOCK|MzYFm!^LOCK|^G$23B
BioNTech SE ADR
BNTX
LOCK|z@MKb@<LOCK|<Y$22B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|DLd^NyLOCK|pg$14B

Sponsor Center